BioAffinity Technologies (BIAF) announced that it has received a written notice from Nasdaq stating that the company has regained compliance with all applicable continued listing requirements.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- bioAffinity Technologies Announces $1.8M Direct Offering
- BioAffinity Technologies announces closing of $1.8M registered direct offering
- BioAffinity Technologies announces $1.8M registered direct offering
- bioAffinity Technologies Reports 95% Sales Surge in Q3 2025
- BioAffinity Technologies reports record growth for CyPath Lung diagnostic test